Boothbay Fund Management’s Galectin Therapeutics GALT Stock Holding History

Boothbay Fund Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-23,749	Closed	-$39.4K	–	1696
2023 Q4	$39.4K	Buy	+23,749	New	+$46.1K	﹤0.01%	1547
2021 Q3	–	Sell	-10,965	Closed	-$35K	–	1996
2021 Q2	$35K	Buy	+10,965	New	+$39K	﹤0.01%	1791
2019 Q2	–	Sell	-15,333	Closed	-$78K	–	787
2019 Q1	$78K	Sell	15,333 -15,229	-50%	-$73.1K	0.01%	671
2018 Q4	$105K	Buy	+30,562	New	+$146K	0.02%	555
2016 Q3	–	Sell	-18,850	Closed	-$28K	–	744
2016 Q2	$28K	Hold	18,850	–	–	0.01%	499
2016 Q1	$27K	Buy	18,850 +6,180	+49%	+$8.3K	0.02%	287
2015 Q4	$21K	Buy	+12,670	New	+$29K	0.01%	544

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Boothbay Fund Management's GALT Position: Q1 2024 in Review

Boothbay Fund Management sold out of Galectin Therapeutics (GALT) in Q1 2024, closing a stake of 23,749 shares — an estimated $39.4K sold.

Boothbay Fund Management first reported a position in GALT in Q4 2015 and held it in 7 quarters. The position peaked at $105K in Q4 2018. 59 funds tracked by Wall St. Rank hold GALT as of Q1 2024.

Boothbay Fund Management reported no remaining Galectin Therapeutics position as of Q1 2024 after selling out during the quarter.
Boothbay Fund Management sold 23,749 Galectin Therapeutics shares in Q1 2024, an estimated $39.4K.
Boothbay Fund Management first reported a position in Galectin Therapeutics in Q4 2015 and held it in 7 quarters.
Boothbay Fund Management's Galectin Therapeutics position peaked at $105K in Q4 2018.
59 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.